

Moderna COVID-19 Vaccines

Vaccine Preparation and Administration Summary



General information

Composition	Age Indications	Cap/label border	Diluent	Use For	Dosage
Monovalent	6 months through 5 years	Blue capped vial/Magenta-bordered label	NONE	Primary series doses	25 µg/0.25 mL
Bivalent	6 months through 5 years	Pink capped vial/Yellow-bordered label	NONE	Booster doses	10 µg/0.2 mL
Monovalent	6 through 11 years*	Blue capped vial/Purple-bordered label	NONE	Primary series dose	50 µg/0.5 mL
Monovalent	12 years and older	Red capped vial/Blue-bordered label	NONE	Primary series doses	100 µg/0.5 mL
Bivalent	6 years and older	Blue capped vial/Gray-bordered label	NONE	Booster doses	6 through 11 years: 25 µg/0.25 mL
					12 years and older: 50 µg/0.5 mL

* Moderna COVID-19 Vaccine supplied in a vial with a dark blue cap and a label with a teal border stating "Age 6y through 11y" is currently not available. Moderna COVID-19 Vaccine supplied in a vial with a dark blue cap and a label with a purple border stating "**BOOSTER DOSES ONLY** Booster dose: 0.5mL" is FDA-authorized for use in children ages 6–11 years as a primary series dose. It is not authorized for the booster dose.

Schedule

Use the [Interim Schedule for Persons 6 Months of Age and Older](#) to determine if a doses is needed or to schedule doses.

Preparation and Administration


Remove vaccine from the storage unit.

- If the vaccine is frozen, allow to thaw before preparing the injection. Thaw vaccine in the refrigerator or at room temperature. Unpunctured vials may be stored:
 - In the refrigerator for up to 30 days OR
 - At room temperature between 8°C and 25°C (46°F and 77°F) for a total of 24 hours
- Do NOT refreeze thawed vaccine.
- Use CDC's beyond-use date labels for this vaccine to track storage time at refrigerated temperatures.
- Choose the correct vaccine product based on the age of the recipient and the dose – primary versus booster. Check the vaccine for age indications and composition of the vaccine (monovalent; bivalent)


Primary series dose



Ages: 6 months through 5 years
Use MONOVALENT vaccine
 (Blue capped vial with magenta-bordered label)
10 doses per vial




Ages: 6 through 11 years
Use MONOVALENT vaccine
 (Blue capped vial with purple-bordered label)
5 doses per vial




Ages: 12 years and older
Use MONOVALENT vaccine
 (Red capped vial with blue-bordered label)
10-11 doses per vial

Booster dose



Ages: 6 months through 5 years
Use BIVALENT vaccine
 (Pink capped vial with yellow-bordered label)
2 doses per vial

These vials contain 2 doses.
 They should not be confused with single dose vials. Once 2 doses have been removed, discard the vial.



Ages: 6 years and older
Use BIVALENT vaccine
 (Blue capped vial with gray-bordered label)
10 doses per vial

Check the vial label to ensure the expiration date or beyond-use date/time has not passed.

- Use Moderna expiration date tool at <https://modernacovid19global.com/vial-lookup>
- Check beyond-use date/times
 - **Unpunctured vials** may be stored between:
 - » 2°C and 8°C (36°F- 46°F) for up to 30 days
 - » 8°C and 25°C (46°F and 77°F) for a total of 24 hours
- **Puncture vials** may be stored between 2°C to 25°C (35°F to 77°F) for up to:
 - » 8 hours - bivalent vaccine for ages 6 months through 5 years (pink capped vials with yellow-bordered labels)
 - » 12 hours - all other Moderna COVID-19 vaccine products
- Do NOT use vaccine if the expiration date or beyond-use date/time has passed

Moderna COVID-19 Vaccines

Vaccine Preparation and Administration Summary



Follow aseptic technique

- Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled. Gloves are not required unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. If worn, perform hand hygiene and change gloves between patients.
- Use a new, sterile needle and syringe for each injection

Gently swirl the thawed vaccine vial. Do not shake the vial.

- The vaccine is white to off-white in color and may contain white or translucent particles. Do not use if liquid contains other particulate matter or is discolored.

COVID-19 vaccine is administered by intramuscular injection.

Choose the correct equipment.

- Needle gauge: 22 -25 gauge
- Needle length varies by recipient's age, gender, weight, and injection site. See chart: [Vaccine Administration: Needle Gauge and Length \(cdc.gov\)](https://www.cdc.gov/vaccines/imz/downloads/pdf/1525n.pdf)

Withdraw the correct dosage.

- If the amount of vaccine remaining in the vial cannot provide a full dose, discard the vial and any excess volume. Do NOT combine from 2 or more vials to obtain a dose

Ages 6 months through 5 years
MONOVALENT
0.25 mL/25 µg

Ages 6 months through 5 years
BIVALENT BOOSTER
0.2 mL/10 µg

Ages 6 through 11 years
MONOVALENT
0.5 mL/50 µg

Ages 6 through 11 years
BIVALENT BOOSTER
0.25 mL/25 µg

Ages 12 and older
MONOVALENT
0.5 mL/100 µg

Ages 12 years and older
BIVALENT BOOSTER
0.5 mL/50 µg

Administer vaccine by intramuscular (IM) injection

Ages	Injection site
6 months through 2 years	Vastus lateralis muscle in the anterolateral thigh
3 years and older	Deltoid muscle in the upper arm. Alternatively, the anterolateral thigh can be used.

Consider observing persons after vaccination to monitor for allergic reactions and syncope:

30 minutes for persons with:

- An allergy-related contraindication to a different type of COVID-19 vaccine
- A history of non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine
- A history of anaphylaxis after non-COVID-19 vaccines or injectable therapies

15 minutes: All other persons

Document the vaccination

Document each recipient's vaccine administration information in the:

- Medical record:
 - Vaccine and the date administered, manufacturer, lot number, vaccination site, and route
 - Name and title of the person administering the vaccine
- Recipient's vaccination record card:
 - Date of vaccination, product name/manufacturer, lot number, and name/location of the administering clinic or healthcare professional. Indicate if the vaccine dose is a monovalent or bivalent product, if possible.
 - Report the vaccination to the appropriate [state/local immunization information system \(IIS\)](#)

Contraindications and precautions

Screen for contraindications and precautions before administering EACH dose — even if the vaccine was previously administered. Use CDC's COVID-19 [Prevaccination Screening Checklist and Guidance](#) to determine if the vaccine may be administered.

Contraindications

History of:

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Known diagnosed allergy to a component of the COVID-19 vaccine



Precautions

History of:

- Anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”])
- Non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of one type of COVID-19 vaccine have a precaution to the same type of COVID-19 vaccine
- An allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the other types of COVID-19 vaccines
- Moderate to severe acute illness, with or without fever
- Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
- Myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine

Report adverse reactions and administration errors

Healthcare professionals are required to report to the [Vaccine Adverse Event Reporting System \(VAERS\)](#) including:

- Vaccine administration errors (whether associated with an adverse event [AE] or not)
- Serious AEs (irrespective of attribution to vaccination)
- Multisystem inflammatory syndrome (MIS) in adults and children
- Cases of myocarditis and pericarditis (for mRNA vaccines)
- Cases of COVID-19 that result in hospitalization or death
- Any additional AEs and revised safety requirements per the Food and Drug Administration’s conditions for use of an authorized vaccine throughout the duration of the EUA

Healthcare professionals are encouraged to report to VAERS clinically important adverse events that occur after vaccination, even if you are not sure whether the vaccine caused the adverse event.